- Conditions
- Prostate Cancer
- Interventions
- Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT), Placebo, Saruparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2036
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 37 more
Condition Directory
Prostate Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
909
Shown on this page
12
Local recruiting
171
Local phase groups
6
Showing 1–12 of 909 matching trials for Prostate Cancer.
Indexed local directory records.
Phase distribution
Phase 2 356
Not applicable 206
Phase 1 198
Phase 3 85
Early Phase 1 20
Phase 4 19
Top locations
Top sponsors
Top therapies
Indexed official records
Open in full search- Conditions
- Advanced Solid Tumor, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Solid Tumor, Renal Pelvis Cancer, Triple Negative Breast Cancer, Urinary Bladder Neoplasm
- Interventions
- LY4052031
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 12 more
- Conditions
- Advanced Prostate Carcinoma, Prostate Cancer
- Interventions
- Hyperpolarized C13, Magnetic Resonance Imaging (MRI)
- Drug · Procedure
- Lead sponsor
- Ivan de Kouchkovsky, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Multiple Myeloma, Prostate Cancer
- Interventions
- mHealth Intervention
- Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer
- Interventions
- Hyperpolarized Carbon C 13 Pyruvate, MRI Ultrasound Fusion Guided Biopsy, Magnetic Resonance Spectroscopic Imaging
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cancer of the Prostate, Neoplasms, Prostate, Prostate Cancer, Prostatic Neoplasm
- Interventions
- AI
- Device
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Cancer of the Prostate, Hormone Sensitive Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Prostate Cancer
- Interventions
- Enzalutamide, Mevrometostat, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 96
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 69 more
- Conditions
- Prostate Cancer, Prostatic Neoplasms
- Interventions
- Docetaxel, Ifinatamab deruxtecan, Prednisone, Rescue Medication
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Duarte, California • Irvine, California + 38 more
- Conditions
- Advanced Solid Tumor, Bladder Cancer, Breast Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Non-small Cell Lung Cancer (NSCLC), Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Cancer
- Interventions
- HER3-DXd
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 13
- States / cities
- Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 10 more
- Conditions
- Prostate Cancer
- Interventions
- GnRH Antagonist, Xaluritamig
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- San Francisco, California • St Louis, Missouri • Columbus, Ohio + 4 more
- Conditions
- Prostate Cancer, Prostatic Neoplasms
- Interventions
- 64Cu-SAR-bisPSMA
- Drug
- Lead sponsor
- Clarity Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 21 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, mCRPC
- Interventions
- 18F-rhPSMA-7.3 injection (in phase 1 only), Lutetium (177Lu) rhPSMA-10.1 Injection
- Diagnostic Test · Drug
- Lead sponsor
- Blue Earth Therapeutics Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 5
- States / cities
- Miami, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
About this Prostate Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Prostate Cancer.